FIELD: medicine, pharmaceutics.
SUBSTANCE: given invention refers to arylamines of formula (I) 
and their pharmaceutically acceptable salts which are active in relation to 5HT receptors, particularly show 5-HT6 modulating activity, and can be used for treating a number of diseases, such as obesity, or the other diseases, for treating 5-HT-associated condition selected from a group containing Alzheimer's disease, Hundington's disease, obesity, obesity-related disorder, insulin-independent diabetes, Alzheimer's disease related cognitive disorders, schizophrenia related cognitive disorders, reflux gastroesophagitis, non-ulcer dyspepsia, depression, anxiety, migraine, gastritis, gastric emptying disorder, eating disorders, gastrointestinal disorders, constipations, panic attacks, memory impairment, disturbed sleep, alcohol-use disorders, anorexia, bulimia, obsessive-compulsive disorders, psychosis, Parkinson's disease, Hundington's chorea, and/or schizophrenia, drug abuse and attention deficit/hyperactivity disorder (ADHD). In the compound of formula (I) n means 1; A means C1-C3alkylene; R1 means hydrogen or C1-C10alkyl; R2 means C1-C10alkoxy, C(O)CF3 or SO2R6, where R6 can be C1-C4 alkyl R3 and R4 independently means hydrogen, substituted or unsubstituted C1-C7alkyl, where a substituted is selected from dihydrobenzodioxidine or benzodioxole, probably substituted by halogen; phenyl, probably substituted by C1-C4alkyl, C1-C4alkoxy, halogen, trifluoromethyl; aryl selected form naphthyl or tetrahydronaphthyl, optionally substituted by C1-C4alkyl, C1-C4alkoxy; heteroaryl, 5-members heteroaryl condensed with the benzoic ring with sulphur atom as a heteroatom, chromanyl probably substituted by halogen; B means a bound; and X and Y means -CH-.
EFFECT: preparing pharmaceutically acceptable salts which are active in relation to 5HT receptors.
59 cl, 9 dwg, 1 tbl, 57 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BICYCLIC COMPOUND AND USE THEREOF FOR SUV39H2 INHIBITION | 2016 |
|
RU2729187C1 |
| INHIBITOR COMPOUNDS | 2013 |
|
RU2673079C2 |
| NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | 2011 |
|
RU2585177C2 |
| SUBSTITUTED PYRROLIDINES AS XIa FACTOR INHIBITORS FOR THROMBOEMBOLIC DISEASES TREATMENT | 2013 |
|
RU2636050C2 |
| FGFR4 INHIBITORS | 2014 |
|
RU2715708C2 |
| NOVEL PHENYL PYRROLE DERIVATIVE | 2009 |
|
RU2470917C2 |
| BROMDOMAIN INHIBITORS | 2012 |
|
RU2671571C1 |
| PYRROLO[2,1-f][1,2,4]TRIAZINE COMPOUND, METHOD FOR PRODUCTION AND USE THEREOF | 2013 |
|
RU2589053C1 |
| COMPOUNDS OF FORMULA (I) AND FORMULA (A), PHARMACEUTICAL COMPOSITION, MEDICINAL PRODUCT, USE AND METHOD OF OBTAINING COMPOUNDS OF FORMULA (I) | 2018 |
|
RU2822758C2 |
| DERIVATIVES OF PIPERAZINE AND METHOD OF THEIR SYNTHESIS | 1997 |
|
RU2146254C1 |
